Literature DB >> 35586426

Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.

Yasuko Koda1, Shin Sato2,3, Hirofumi Yamamoto1, Hideaki Niwa2,3, Hisami Watanabe2,3, Chiduru Watanabe4, Tomohiro Sato4, Kana Nakamura3, Akiko Tanaka3, Mikako Shirouzu3, Teruki Honma4, Takehiro Fukami5, Hiroo Koyama1, Takashi Umehara2,3.   

Abstract

Lysine-specific demethylase 1 (LSD1/KDM1A) is a promising therapeutic target for the treatment of cancers. Several derivatives of tranylcypromine (trans-2-phenylcyclopropylamine) have been developed as LSD1 inhibitors. One such derivative is S2157; however, this compound has a high hERG channel inhibitory activity and a low microsomal stability, making it unsuitable as a drug candidate. Here, using an in silico hERG inhibition prediction model, we designed, synthesized, and evaluated a novel series of S2157 derivatives characterized by modifications of the benzyloxy and piperazine groups. Among the synthesized derivatives, a compound possessing 2-fluoropyridine and 2,8-diaza-spiro[4.5]decane groups (compound 10) showed the most desirable activities, and its eutomer, S1427, was isolated by the optical resolution of 10. In addition to potent LSD1 inhibitory activity, S1427 exhibited desirable hERG channel inhibition and microsomal stability profiles.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35586426      PMCID: PMC9109268          DOI: 10.1021/acsmedchemlett.2c00120

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  30 in total

1.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Authors:  Tino Schenk; Weihsu Claire Chen; Stefanie Göllner; Louise Howell; Liqing Jin; Katja Hebestreit; Hans-Ulrich Klein; Andreea C Popescu; Alan Burnett; Ken Mills; Robert A Casero; Laurence Marton; Patrick Woster; Mark D Minden; Martin Dugas; Jean C Y Wang; John E Dick; Carsten Müller-Tidow; Kevin Petrie; Arthur Zelent
Journal:  Nat Med       Date:  2012-03-11       Impact factor: 53.440

Review 2.  Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases.

Authors:  Nima Mosammaparast; Yang Shi
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

3.  Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.

Authors:  Min Gyu Lee; Christopher Wynder; Dawn M Schmidt; Dewey G McCafferty; Ramin Shiekhattar
Journal:  Chem Biol       Date:  2006-06

Review 4.  A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.

Authors:  Yi-Chao Zheng; Jinlian Ma; Zhiru Wang; Jinfeng Li; Bailing Jiang; Wenjuan Zhou; Xiaojing Shi; Xixin Wang; Wen Zhao; Hong-Min Liu
Journal:  Med Res Rev       Date:  2015-05-19       Impact factor: 12.944

5.  ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.

Authors:  Tamara Maes; Cristina Mascaró; Iñigo Tirapu; Angels Estiarte; Filippo Ciceri; Serena Lunardi; Nathalie Guibourt; Alvaro Perdones; Michele M P Lufino; Tim C P Somervaille; Dan H Wiseman; Cihangir Duy; Ari Melnick; Christophe Willekens; Alberto Ortega; Marc Martinell; Nuria Valls; Guido Kurz; Matthew Fyfe; Julio Cesar Castro-Palomino; Carlos Buesa
Journal:  Cancer Cell       Date:  2018-03-01       Impact factor: 31.743

6.  Structure-Based Identification of Potent Lysine-Specific Demethylase 1 Inhibitor Peptides and Temporary Cyclization to Enhance Proteolytic Stability and Cell Growth-Inhibitory Activity.

Authors:  Hiroki Kitagawa; Masaki Kikuchi; Shin Sato; Hisami Watanabe; Naoki Umezawa; Maiko Kato; Yosuke Hisamatsu; Takashi Umehara; Tsunehiko Higuchi
Journal:  J Med Chem       Date:  2021-03-23       Impact factor: 7.446

7.  Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.

Authors:  Mario L Suvà; Esther Rheinbay; Shawn M Gillespie; Anoop P Patel; Hiroaki Wakimoto; Samuel D Rabkin; Nicolo Riggi; Andrew S Chi; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; Miguel N Rivera; Nikki Rossetti; Simon Kasif; Samantha Beik; Sabah Kadri; Itay Tirosh; Ivo Wortman; Alex K Shalek; Orit Rozenblatt-Rosen; Aviv Regev; David N Louis; Bradley E Bernstein
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

8.  trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.

Authors:  Dawn M Z Schmidt; Dewey G McCafferty
Journal:  Biochemistry       Date:  2007-03-17       Impact factor: 3.162

Review 9.  Recent Progress in Histone Demethylase Inhibitors.

Authors:  Tom E McAllister; Katherine S England; Richard J Hopkinson; Paul E Brennan; Akane Kawamura; Christopher J Schofield
Journal:  J Med Chem       Date:  2016-02-02       Impact factor: 7.446

10.  Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.

Authors:  Chao Zhou; Fangrui Wu; Lianghao Lu; Liping Wei; Eric Pai; Yuan Yao; Yongcheng Song
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

View more
  3 in total

1.  Virtual Special Issue: Epigenetics 2022.

Authors:  Courtney C Aldrich; Félix Calderón; Stuart J Conway; Chuan He; Jacob M Hooker; Donna M Huryn; Craig W Lindsley; Dennis C Liotta; Christa E Müller
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-09

2.  Virtual Special Issue: Epigenetics 2022.

Authors:  Courtney C Aldrich; Félix Calderón; Stuart J Conway; Chuan He; Jacob M Hooker; Donna M Huryn; Craig W Lindsley; Dennis C Liotta; Christa E Müller
Journal:  ACS Med Chem Lett       Date:  2022-10-13       Impact factor: 4.632

3.  Structure-Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD2.

Authors:  Hideaki Niwa; Chiduru Watanabe; Shin Sato; Toshiyuki Harada; Hisami Watanabe; Ryo Tabusa; Shunsuke Fukasawa; Ayane Shiobara; Tomoko Hashimoto; Osamu Ohno; Kana Nakamura; Keiko Tsuganezawa; Akiko Tanaka; Mikako Shirouzu; Teruki Honma; Kenji Matsuno; Takashi Umehara
Journal:  ACS Med Chem Lett       Date:  2022-08-18       Impact factor: 4.632

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.